STUDY SEARCH RESULTS

1 study found for your search request:  3475-811

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2...
Condition: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT03615326
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site